Catalan Institute of Oncology Institute Catala dOncologia ICO

Spain

Catalan Institute of Oncology Institute Catala dOncologia ICO

Spain
SEARCH FILTERS
Time filter
Source Type

Xavier Bosch F.,Catalan Institute of Oncology Institute Catala dOncologia ICO | de Sanjose S.,Catalan Institute of Oncology Institute Catala dOncologia ICO | de Sanjose S.,CIBER ISCIII | Castellsague X.,Catalan Institute of Oncology Institute Catala dOncologia ICO | Castellsague X.,CIBER ISCIII
Cancer Discovery | Year: 2011

Herrero and colleagues show that in a phase III randomized trial in Guanacaste, Costa Rica, the use of a human papillomavirus type 16 (HPV16) and HPV18 ASO4-adjuvanted vaccine (Cervarix) resulted in complete efficacy against 12-month persistent HPV16 and HPV18 infections and partial protection against HPV31, 33, and 45 in HPV-naïve young women ages 18 to 25. © 2011 American Association for Cancer Research.

Loading Catalan Institute of Oncology Institute Catala dOncologia ICO collaborators
Loading Catalan Institute of Oncology Institute Catala dOncologia ICO collaborators